Three different LDL apheresis columns efficiently and equally reduce lipoprotein(a) concentrations in patients with familial hypercholesterolemia and small apolipoprotein(a) particles-Reference-Cited by-同舟云学术

Three different LDL apheresis columns efficiently and equally reduce lipoprotein(a) concentrations in patients with familial hypercholesterolemia and small apolipoprotein(a) particles

Published:2012-02 Issue:1 Volume:46 Page:73-76
ISSN:1473-0502
Container-title:Transfusion and Apheresis Science
language:en
Short-container-title:Transfusion and Apheresis Science

Author:

Hovland Anders,Marcovina Santica,Hardersen Randolf,Enebakk Terje,Mollnes Tom Eirik,Lappegård Knut Tore

Publisher

Elsevier BV

Subject

Hematology

Reference31 articles.

1. Heart disease and stroke statistics – 2011 update: a report from the American Heart Association;Roger;Circulation,2011

2. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999;142:105-112.

3. Lipoprotein(a) and ischemic heart disease – a causal association? A review;Kamstrup;Atherosclerosis,2010

4. Lipoprotein(a) as a cardiovascular risk factor: current status;Nordestgaard;Eur Heart J,2010

5. Do we know when and how to lower lipoprotein(a)?;Joshi;Curr Treat Options Cardiovasc Med,2010

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Apheresis for Management of Lp(a) Hyperlipoproteinemia;Current Atherosclerosis Reports;2020-09-18

2. Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice;Current Atherosclerosis Reports;2019-07-27

3. Role of Lipoprotein Apheresis in Cardiovascular Disease Risk Reduction;Blood Purification;2019

4. Prospective crossover study for a standardized comparison of the dextrane sulfate whole blood and plasma apheresis system in patients with cardiovascular disease and severe dyslipidemia;Atherosclerosis Supplements;2017-11

5. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol;Atherosclerosis;2016-08